)
Praxis Precision Medicines (PRAX) investor relations material
Praxis Precision Medicines UBS Global Biopharma Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Portfolio and growth strategy
Two NDAs and 21 programs; ulixacaltamide, referred to as Ulixa, is the portfolio’s near-term focus, with essential tremor affecting 9 million Americans.
Three ulixacaltamide extension studies are starting soon in restless legs syndrome, Parkinson’s tremor and autism spectrum disorder; management described restless legs as clinically higher-risk but attractive on risk-reward.
The potential essential tremor market was characterized as $36 billion, versus a prior $10 billion estimate; the launch plan emphasizes controlled patient experience and broad prescribing-base coverage.
Ulixacaltamide regulatory and clinical outlook
Ahead of the January 29 PDUFA, management said the late-cycle FDA meeting felt more like a label discussion and expressed high confidence in approval; further work includes final label and possible PMC/PMR agreements.
Management described the expected label as broad: adult essential tremor studies showed all subgroups nominally superior to placebo, with no expected renal, hepatic or CYP3A4-related restrictions, contraindications, black box warning or REMS.
Management said scheduling is likely, while noting possible Schedule IV, Schedule V or no scheduling; it expects no meaningful launch difference, with neurologists as the target prescribers.
Long-term follow-up showed sustained improvement; the goal is ~200 patients with two years of follow-up, with more data expected soon and potentially in early January. Ulixacaltamide is intended as chronic treatment.
Initial dizziness and brain fog can be challenging for some patients but reportedly improve with continued treatment; launch strategy prioritizes managing that experience while generating demand.
Commercial readiness
Praxis Horizon is operational and has completed end-to-end test scripts, integrating prescribing through dispensing and reimbursement workflows.
The system is designed to support prescribing in physicians’ EMRs, automate prior-authorization data transfer and route prescriptions through a Praxis pharmacy, reducing paperwork and prescription attrition.
Management plans significant launch resources and coverage of the full prescribing base, aiming to balance demand generation with controlled patient experience.
- Two near-term launches anchor a pipeline with >$20B in peak-sales guidance.PRAX
Investor Day 2026 - Ulixacaltamide nears a January decision as launches and pipeline programs advance.PRAX
3rd Annual Guggenheim Healthcare Innovation Conference - Two NDAs near FDA decisions as $1.3B in liquidity supports operations into 2028.PRAX
Q3 2026 - $1.4B cash, late-stage FDA reviews, and commercial readiness drive 2027 launch plans.PRAX
Q2 2026 - Four CNS therapies with blockbuster potential target >$20B peak sales by 2028.PRAX
Corporate presentation - Pivotal epilepsy studies and a robust pipeline set up multiple clinical catalysts through early 2026.PRAX
Jefferies Global Healthcare Conference 2025 - Accelerated clinical and regulatory strategies are driving earlier market entry for key therapies.PRAX
Fireside Chat - Two NDAs filed, strong clinical data, and $1.5B cash position support 2026 launches.PRAX
Q4 2025 - Multiple late-stage clinical readouts and $433.8M cash support operations into 2027.PRAX
Q2 2024
Next Praxis Precision Medicines earnings date
Next Praxis Precision Medicines earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)